Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation

Diabetes Technology and Therapeutics

Volumn 13, Issue 6, 2011, Pages 615-623

  Rudovich, Natalia N ^a,b   Weickert, Martin O ^a,b,c,d   Pivovarova, Olga ^a,b   Bernigau, Wolfgang ^a   Pfeiffer, Andreas F H ^a,b  

^a GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADIPONECTIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROINSULIN;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC LOAD; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACARBOSE; ADIPONECTIN; ALPHA-GLUCOSIDASES; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MIDDLE AGED; OVERWEIGHT; PROINSULIN; SEVERITY OF ILLNESS INDEX;

EID: 79957604680     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2010.0235     Document Type: Article

References (49)

1. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-169. (Pubitemid 27051554)
2. Nakagami T; DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47: 385-394. (Pubitemid 38491233)
3. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
4. Salmerón J, Manson JE, Stampfer MJ, Colditz GA, Wing AL, Willett WC: Dietary fiber, glycemic load, and risk of noninsulin-dependent diabetes mellitus in women. JAMA 1997; 277:472-477. (Pubitemid 27074331)
5. Leeds AR: Glycemic index and heart disease. Am J Clin Nutr 2002;76:286S-289S.
6. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 2002;359:2072-2077. (Pubitemid 34680970)
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494. (Pubitemid 37430502)
8. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16. (Pubitemid 38055587)
9. Delorme S, Chiasson J-L: Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus. Curr Opin Pharmacol 2005;5:184-189. (Pubitemid 40378751)
10. Lebovitz HE: Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors. Drugs 1992;44(Suppl 3):21-28.
11. Radziuk J, Kemmer F, Morishima T, Berchtold P, Vranic M: The effects of an alpha-glucoside hydrolase inhibitor on glycemia and the absorption of sucrose in man determined using a tracer method. Diabetes 1984;33:207-213. (Pubitemid 14196207)
12. Rosak C, Mertes G: Effects of acarbose on proinsulin and insulin secretion and their potential significance for the intermediary metabolism and cardiovascular system. Curr Diabetes Rev 2009;5:157-164.
13. Enç FY, Imeryüz N, Akin L, Turoǧlu T, Dede F, Haklar G, Tekeşin N, Bekiroǧlu N, Yeǧen BC, Rehfeld JF, Holst JJ, Ulusoy NB: Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001;281: G752-G763.
14. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, Cohen RM, Wolever TM: The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190-1193. (Pubitemid 26363430)
15. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A: Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002;28:195-200. (Pubitemid 34746953)
16. Meneilly GS, Ryan EA, Radziuk J, Lau DC, Yale JF, Morais J, Chiasson JL, Rabasa-Lhoret R, Maheux P, Tessier D, Wolever T, Josse RG, Elahi D: Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162-1167. (Pubitemid 30616806)
17. Nijpels G, Boorsma W, Dekker JM, Kostense PJ, Bouter LM, Heine RJ: A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI). Diabetes Metab Res Rev 2008;24:611-616.
18. Fischer S, Patzak A, Rietzsch H, Schwanebeck U, Köhler C, Wildbrett J, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M: Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab 2003;5:38-44.
19. Jenney A, Proietto J, ODea K, Nankervis A, Traianedes K, D'Embden H: Low-dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993;16:499-502. (Pubitemid 23046642)
20. Rosen ED, Spiegelman BM: Adipocytes as regulators of energy balance and glucose homeostasis. Nature 2006;444: 847-853. (Pubitemid 46024991)
21. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA: Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-4319. (Pubitemid 39244431)
22. Möhlig M, Wegewitz U, Osterhoff M, Isken F, Ristow M, Pfeiffer AF, Spranger J: Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002;34:655-658. (Pubitemid 36398702)
23. Krssak M, Falk Petersen K, Dresner A, DiPietro L, Vogel SM, Rothman DL, Roden M, Shulman GI: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42:113-116. (Pubitemid 29039748)
24. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE: Brain adipocytokine action and metabolic regulation. Diabetes 2006;55(Suppl 2):S145-S154. (Pubitemid 44927045)
25. Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47: 201-210. (Pubitemid 43471964)
26. Hotamisligil GS: Inflammation and metabolic disorders. Nature 2006;444:860-867. (Pubitemid 46024993)
27. Fernandez-Real JM, Pickup JC: Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2008;19:10-16.
28. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Paolisso G, Giugliano D: Circulating adhesion molecules in humans: a role of hyperglycemia and hyperinsulinemia. Circulation 2000;101:2247-2251. (Pubitemid 30317125)
29. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-2072. (Pubitemid 35192812)
30. Chettab K, Zibara K, Belaiba SR, McGregor JL: Acute hyperglycaemia induces changes in the transcription levels of 4 major genes in human endothelial cells: macroarrays-based expression analysis. Thromb Haemost 2002;87:141-148. (Pubitemid 34092589)
31. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V: Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78.
32. Spranger J, Kroke A,MöhligM, Hoffmann K, BergmannMM, Ristow M, Boeing H, Pfeiffer AF: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003;52:812-817. (Pubitemid 36323590)
33. Gonzalez-Quesada C, Frangogiannis NG: Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. Curr Atheroscler Rep 2009;11:131-138.
34. Ray KK, Cannon CP, Morrow DA, Kirtane AJ, Buros J, Rifai N, McCabe CH, Gibson CM, Braunwald E: Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18. Eur Heart J 2007;28:806-813. (Pubitemid 47343593)
35. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2000; 23(Suppl 1):S4-S19.
36. Koebnick C, Wagner K, Thielecke F, Dieter G, Höhne A, Franke A, Garcia AL, Meyer H, Hoffmann I, Leitzmann P, Trippo U, Zunft HJ: An easy-to-use semiquantitative food record validated for energy intake by using doubly labelled water technique. Eur J Clin Nutr 2005;59:989-995. (Pubitemid 43118158)
37. De Fronzo RA, Tobin JD, Anders R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223. (Pubitemid 9249478)
38. Senn S: Cross-Over Trials in Clinical Research, 2nd ed. Chichester, UK: John Wiley & Sons, 2002.
39. Shen D, Lu Z: Estimate Carryover Effect in Clinical Trial Crossover Designs. www.lexjansen.com/pharmasuig/2006/ posters/po16.pdf (accessed March 3, 2008).
40. Bacha F, Saad R, Gungor N, Arslanian SA: Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004;27:547-552. (Pubitemid 38174085)
41. Ferrannini E, Muscelli E, Natali A, Gabriel R, Mitrakou A, Flyvbjerg A, Golay A, Hojlund K; Relationship between Insulin Sensitivity and Cardiovascular Disease Risk (RISC) Project Investigators: Association of fasting glucagon and proinsulin concentrations with insulin resistance. Diabetologia 2007;50:2342-2347.
42. Pfützner A, Kunt T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Forst T: Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes. Diabetes Care 2004;27:682-687. (Pubitemid 38280533)
43. Langenfeld MR, Forst T, Standl E, Strotmann HJ, Lübben G, Pahler S, Kann P, Pfützner A; IRIS II Study: IRIS II Study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther 2004;6:836-843. (Pubitemid 40129331)
44. Ochiai H, Ooka H, Shida C, Ishikawa T, Inoue D, Okazaki R: Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocr J 2008;55:549-556. (Pubitemid 351949751)
45. Shimazu T, Inami N, Satoh D, Kajiura T, Yamada K, Iwasaka T, Nomura S: Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients. J Thromb Thrombolysis 2009;28:429-435.
46. Nakamura K, Yamagishi S, Matsui T, Yoshida T, Imaizumi T, Makino T, Shimizu T, Inoue H: Acarbose, an alphaglucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats. J Int Med Res 2006;34:525-530. (Pubitemid 44756140)
47. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T: Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008;57:1299-1306.
48. Kato T, Inoue T, Node K: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol 2010;24:9-12.
49. Holst JJ, Vilsboll T, Deacon CF: The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136.